RxDoctor Payments Data

Mary Strawn, MD

Internal Medicine · Birmingham, ALNPI 1982678868

Payments from drug & device makers

$372in general payments, 2019–2025

Across 21 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$142
  • Astellas Pharma US Inc$49
  • Amgen$48
  • AbbVie$44
  • Endogastric Solutions, Inc$30
  • Novartis$17
  • plus $43 from 3 others

What the payments were for

  • Food & beverage$372100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$372 in reported general payments places this provider in the 45th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$135,104
Medicare patients
251
Services billed
8,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban132$98,760
JanuviaSitagliptin Phosphate117$90,387
OzempicSemaglutide80$86,809
MounjaroTirzepatide77$80,192
TrulicityDulaglutide37$33,609
MyrbetriqMirabegron62$32,180
FarxigaDapagliflozin Propanediol17$16,312
RybelsusSemaglutide14$13,176
GemtesaVibegron25$12,196
LinzessLinaclotide19$11,131
Atorvastatin Calcium713$10,452
Rosuvastatin Calcium425$8,161
Lantus SolostarInsulin Glargine,hum.Rec.Anlog82$8,003
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$7,653
Valsartan175$5,449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$13$99,98694 claims
PfizerEliquis$142$98,760132 claims
Astellas Pharma US IncMyrbetriq$49$32,18062 claims
AbbVieLinzess, Synthroid$44$14,50474 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →